Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine

Lancet. 2001 Dec;358(9299):2127-8. doi: 10.1016/S0140-6736(01)07184-7.


Asymmetrical dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor, which has been suggested to be a novel independent risk factor for endothelial dysfunction and coronary heart disease. We investigated the association of ADMA concentration in serum with risk of acute coronary events. We did a prospective, nested, case-control study in middle-aged men from eastern Finland. In an analysis of men who did not smoke, those who were in the highest quartile for ADMA (>0.62 micromol/L) had a 3.9-fold (95% CI 1.25-12.3, p=0.02) increase in risk of acute coronary events compared with the other quartiles. Our findings suggest that ADMA is a predictor of acute coronary events.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Arginine / blood*
  • Coronary Disease / blood*
  • Endothelium, Vascular / physiopathology
  • Humans
  • Male
  • Middle Aged
  • Risk Assessment


  • Arginine